BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oyebanji OA, Wilson B, Keresztesy D, Carias L, Wilk D, Payne M, Aung H, Denis KS, Lam EC, Rowley CF, Berry SD, Cameron CM, Cameron MJ, Schmader KE, Balazs AB, King CL, Canaday DH, Gravenstein S. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? Aging Clin Exp Res 2021;33:3151-60. [PMID: 34652783 DOI: 10.1007/s40520-021-01987-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Choi MJ, Heo JY, Seo YB, Yoon YK, Sohn JW, Noh JY, Cheong HJ, Kim WJ, Choi JY, Lee YJ, Lee HW, Kim SS, Kim B, Song JY. Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study. Vaccines (Basel) 2023;11. [PMID: 36679965 DOI: 10.3390/vaccines11010120] [Reference Citation Analysis]
2 Brook B, Fatou B, Checkervarty A, Barman S, Sweitzer C, Bosco AN, Sherman A, Baden LR, Morrocchi E, Sanchez-Schmitz G, Palma P, Nanishi E, O'Meara T, McGrath M, Frieman M, Soni D, van Haren S, Ozonoff A, Diray-Arce J, Steen H, Dowling D, Levy O. The mRNA vaccine BNT162b2 demonstrates impaired TH1 immunogenicity in human elders in vitro and aged mice in vivo. Res Sq 2022:rs. [PMID: 36597547 DOI: 10.21203/rs.3.rs-2395118/v1] [Reference Citation Analysis]
3 Braun E, Horowitz NA, Leiba R, Weissman A, Mekel M, Shachor-Meyouhas Y, Hussein K, Halberthal M, Azzam ZS, Berger G. Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses. Clin Microbiol Infect 2022;28:1644-8. [PMID: 35843565 DOI: 10.1016/j.cmi.2022.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Oyebanji OA, Mylonakis E, Canaday DH. Vaccines for the prevention of COVID-19 in older adults. Infectious Disease Clinics of North America 2022. [DOI: 10.1016/j.idc.2022.11.002] [Reference Citation Analysis]
5 Takano T, Sato T, Kotaki R, Moriyama S, Shinoda M, Kabasawa K, Shimada N, Kousaka M, Adachi Y, Onodera T, Terahara K, Isogawa M, Matsumura T, Shinkai M, Takahashi Y. Heterologous booster immunization with SARS-CoV-2 spike protein after mRNA vaccine elicits durable and broad antibody responses.. [DOI: 10.21203/rs.3.rs-2014078/v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Takahashi W, Mizuno T, Hara K, Ara Y, Hurutani R, Agatsuma T, Fujimori M. Association of Systemic Adverse Reactions and Serum SARS-CoV-2 Spike Protein Antibody Levels after Administration of BNT162b2 mRNA COVID-19 Vaccine. Intern Med 2022. [PMID: 35989281 DOI: 10.2169/internalmedicine.9699-22] [Reference Citation Analysis]
7 Hatzakis A, Karabinis A, Roussos S, Pantazis N, Degiannis D, Chaidaroglou A, Petsios K, Pavlopoulou I, Tsiodras S, Paraskevis D, Sypsa V, Psichogiou M. Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. Vaccines 2022;10:285. [DOI: 10.3390/vaccines10020285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Uwamino Y, Kurafuji T, Sato Y, Tomita Y, Shibata A, Tanabe A, Yatabe Y, Noguchi M, Arai T, Ohno A, Yokota H, Yamasawa W, Uno S, Nishimura T, Hasegawa N, Saya H, Wakui M, Murata M; Keio Donner Project Team. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff. Vaccine 2022;40:1019-25. [PMID: 35033389 DOI: 10.1016/j.vaccine.2022.01.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]